ObjectiveKINDLE‐Korea is part of a real‐world KINDLE study that aimed to characterize the treatment patterns and clinical outcomes of patients with stage III non‐small cell lung cancer (NSCLC).Materials and MethodsThe KINDLE was an international real‐world study that explores patient and disease characteristics, treatment patterns, and survival outcomes. The KINDLE‐Korea included stage III NSCLC patients diagnosed between January 2013 and December 2017.ResultsA total of 461 patients were enrolled. The median age was 66 years (range: 24–87). Most patients were men (75.7%) with a history of smoking (74.0%), stage IIIA NSCLC (69.2%), and unresectable disease (52.9%). A total of 24.3% had activating EGFR mutation and 62.2% were positive for PDL1 expression. Broadly categorized, 44.6% of the patients received chemoradiation (CRT)‐based therapy, 35.1% underwent surgery, and 20.3% received palliative therapies as initial treatment. The most commonly adopted approaches for patients with stage IIIA and IIIB disease were surgery and CRT, respectively. The median PFS was 15.2 months and OS was 66.7 months. Age >65 years, adenocarcinoma histology, and surgery as the initial treatment were significantly associated with longer OS.ConclusionThis study revealed the heterogeneity of treatment patterns and survival outcomes in patients with stage III NSCLC before durvalumab consolidation came into clinical practice. There is an unmet need for patients who are not eligible for surgery as an initial therapy. Novel therapeutic approaches are highly warranted to improve clinical outcomes.

中文翻译：

---

韩国 III 期 NSCLC 患者的真实治疗模式和临床结果：KINDLE 研究

目的 KINDLE-Korea 是真实世界 KINDLE 研究的一部分，旨在描述 III 期非小细胞肺癌 (NSCLC) 患者的治疗模式和临床结果。材料和方法 KINDLE 是一项国际真实世界研究，旨在探讨患者和疾病特征、治疗模式和生存结果。 KINDLE-Korea纳入了2013年1月至2017年12月期间诊断的III期NSCLC患者。结果共有461名患者入组。中位年龄为 66 岁（范围：24-87 岁）。大多数患者是男性（75.7%），有吸烟史（74.0%）、IIIA期非小细胞肺癌（69.2%）和无法切除的疾病（52.9%）。总共 24.3% 的患者具有激活的 EGFR 突变，62.2% 的患者 PDL1 表达呈阳性。大致分类，44.6% 的患者接受放化疗 (CRT) 治疗，35.1% 接受手术，20.3% 接受姑息治疗作为初始治疗。 IIIA 期和 IIIB 期疾病患者最常用的治疗方法分别是手术和 CRT。中位 PFS 为 15.2 个月，OS 为 66.7 个月。年龄 > 65 岁、腺癌组织学和手术作为初始治疗与更长的 OS 显着相关。结论这项研究揭示了在 durvalumab 巩固进入临床实践之前 III 期 NSCLC 患者的治疗模式和生存结果的异质性。对于不适合接受手术作为初始治疗的患者来说，其需求尚未得到满足。新的治疗方法对于改善临床结果非常有必要。